172 related articles for article (PubMed ID: 8893887)
1. Phase II activity of gemcitabine in advanced breast cancer.
Carmichael J; Walling J
Semin Oncol; 1996 Oct; 23(5 Suppl 10):77-81. PubMed ID: 8893887
[TBL] [Abstract][Full Text] [Related]
2. Advanced breast cancer: a phase II trial with gemcitabine.
Carmichael J; Possinger K; Phillip P; Beykirch M; Kerr H; Walling J; Harris AL
J Clin Oncol; 1995 Nov; 13(11):2731-6. PubMed ID: 7595731
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine in advanced breast cancer.
Possinger K
Anticancer Drugs; 1995 Dec; 6 Suppl 6():55-9. PubMed ID: 8718426
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Possinger K; Kaufmann M; Coleman R; Stuart NS; Helsing M; Ohnmacht U; Arning M
Anticancer Drugs; 1999 Feb; 10(2):155-62. PubMed ID: 10211545
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.
Rha SY; Moon YH; Jeung HC; Kim YT; Sohn JH; Yang WI; Suh CO; Kim GE; Roh JK; Chung HC
Breast Cancer Res Treat; 2005 Apr; 90(3):215-21. PubMed ID: 15830134
[TBL] [Abstract][Full Text] [Related]
6. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
[TBL] [Abstract][Full Text] [Related]
7. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
[TBL] [Abstract][Full Text] [Related]
8. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and vinorelbine combination in patients with metastatic breast cancer.
Sanal SM; Gokmen E; Karabulut B; Sezgin C
Breast J; 2002; 8(3):171-6. PubMed ID: 12047474
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study.
Lüftner D; Flath B; Akrivakis C; Mergenthaler HG; Ohnmacht U; Arning M; Possinger K
Invest New Drugs; 1998; 16(2):141-6. PubMed ID: 9848577
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Murad AM
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Passardi A; Massa I; Zoli W; Gianni L; Milandri C; Zumaglini F; Nanni O; Maltoni R; Frassineti GL; Amadori D
BMC Cancer; 2006 Mar; 6():76. PubMed ID: 16551351
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of gemcitabine in patients with advanced pancreatic cancer.
Carmichael J; Fink U; Russell RC; Spittle MF; Harris AL; Spiessi G; Blatter J
Br J Cancer; 1996 Jan; 73(1):101-5. PubMed ID: 8554969
[TBL] [Abstract][Full Text] [Related]
14. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.
Schmid P; Akrivakis K; Flath B; Grosse Y; Sezer O; Mergenthaler HG; Possinger K
Anticancer Drugs; 1999 Aug; 10(7):625-31. PubMed ID: 10507311
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
Delfino C; Caccia G; Riva Gonzáles L; Mickiewicz E; Rodger J; Balbiani L; Flores Morales D; Zori Comba A; Brosio C
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):22-5. PubMed ID: 14768401
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
20. Advanced breast cancer: investigational role of gemcitabine.
Carmichael J; Walling J
Eur J Cancer; 1997 Jan; 33 Suppl 1():S27-30. PubMed ID: 9166097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
